Coronary artery disease is the largest cause of premature death in the Western world. Lipid-lowering therapy with statins has revolutionized the management of this condition over the past decade.
Successive clinical trials have lowered the treatment bar for statin therapy in patients with coronary artery disease. In addition to traditional markers of efficacy such as low-density lipoprotein cholesterol, emerging targets such as C-reactive protein are becoming recognized as important therapeutic goals.
This review focuses on the important contributions to the literature during the past year and provides an expert opinion of the therapeutic goals for statin therapy.
Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA
CPC has received research grants from Bristol-Myers Squibb, Pfizer, Merck, Sanofi-Aventis, and Astra-Zeneca; KKR has received research grants from Bristol-Myers Squibb, Pfizer, and Sanofi-Aventis and is funded by a British Heart Foundation International Fellowship
Correspondence to Kausik K Ray, TIMI Study Group, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
Tel: 617 525 6865; fax: 617 734 7329; e-mail: firstname.lastname@example.org